{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:49:06Z","timestamp":1762177746166,"version":"3.30.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.bmcl.2024.130008","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T20:08:04Z","timestamp":1730318884000},"page":"130008","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Extended structure-activity relationship studies of the [1,2,5]oxadiazolo[3,4-b]pyrazine-containing colistin adjuvants"],"prefix":"10.1016","volume":"115","author":[{"given":"Susan L.","family":"Harris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somnath","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nianzi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tilmann","family":"Wollenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2024.130008_b0005","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.bmcl.2024.130008_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050","author":"Naghavi","year":"2024","journal-title":"Lancet"},{"volume":"vol. 2","year":"2017","author":"Jonas","key":"10.1016\/j.bmcl.2024.130008_b0015"},{"key":"10.1016\/j.bmcl.2024.130008_b0020","unstructured":"CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019."},{"key":"10.1016\/j.bmcl.2024.130008_b0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy: J Human Pharmacol Drug Therapy"},{"key":"10.1016\/j.bmcl.2024.130008_b0030","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1086\/592412","article-title":"Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies","volume":"29","author":"Patel","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"2","key":"10.1016\/j.bmcl.2024.130008_b0035","doi-asserted-by":"crossref","first-page":"ofv050","DOI":"10.1093\/ofid\/ofv050","article-title":"Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections.","volume":"2","author":"Morrill","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.bmcl.2024.130008_b0040","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1185\/03007995.2015.1018989","article-title":"Colistin, mechanisms and prevalence of resistance","volume":"31","author":"Bialvaei","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.bmcl.2024.130008_b0045","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1086\/429323","article-title":"Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-Negative Bacterial Infections","volume":"40","author":"Falagas","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bmcl.2024.130008_b0050","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3389\/fmicb.2014.00643","article-title":"Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria","volume":"5","author":"Olaitan","year":"2014","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bmcl.2024.130008_b0055","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ijantimicag.2016.06.023","article-title":"Molecular mechanisms of polymyxin resistance: knowns and unknowns","volume":"48","author":"Baron","year":"2016","journal-title":"Int J Antimicrob Agents"},{"year":"2021","series-title":"GLASS: the detection and reporting of colistin resistance","author":"World Health Organization","key":"10.1016\/j.bmcl.2024.130008_b0060"},{"key":"10.1016\/j.bmcl.2024.130008_b0065","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41467-018-03205-z","article-title":"The global distribution and spread of the mobilized colistin resistance gene mcr-1","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2024.130008_b0070","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ijmm.2013.02.001","article-title":"Plasmids and the spread of resistance","volume":"303","author":"Carattoli","year":"2013","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.bmcl.2024.130008_b0075","doi-asserted-by":"crossref","first-page":"15573","DOI":"10.1073\/pnas.1310459110","article-title":"Bio-inspired synthesis yields a tricyclic indoline that selectively resensitizes methicillin-resistant Staphylococcus aureus (MRSA) to \u03b2-lactam antibiotics","volume":"110","author":"Podoll","year":"2013","journal-title":"PNAS"},{"key":"10.1016\/j.bmcl.2024.130008_b0080","doi-asserted-by":"crossref","first-page":"e0005123","DOI":"10.1128\/aac.00051-23","article-title":"A small-molecule membrane fluidizer re-sensitizes methicillin-resistant Staphylococcus aureus (MRSA) to \u03b2-lactam antibiotics","volume":"67","author":"Podoll","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2024.130008_b0085","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1021\/acsinfecdis.7b00071","article-title":"The Challenge of Overcoming Antibiotic Resistance: An Adjuvant Approach?","volume":"3","author":"Melander","year":"2017","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmcl.2024.130008_b0090","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1038\/s41467-020-18939-y","article-title":"Resensitizing carbapenem- and colistin-resistant bacteria to antibiotics using auranofin","volume":"11","author":"Sun","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2024.130008_b0095","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/s41564-020-0723-z","article-title":"A broad-spectrum antibiotic adjuvant reverses multidrug-resistant Gram-negative pathogens","volume":"5","author":"Song","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.bmcl.2024.130008_b0100","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1021\/acsinfecdis.9b00212","article-title":"Repurposing Eukaryotic Kinase Inhibitors as Colistin Adjuvants in Gram-Negative Bacteria","volume":"5","author":"Barker","year":"2019","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmcl.2024.130008_b0105","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1021\/acsinfecdis.2c00417","article-title":"Re-sensitization of Multidrug-Resistant and Colistin-Resistant Gram-Negative Bacteria to Colistin by Povarov\/Doebner-Derived Compounds","volume":"9","author":"Onyedibe","year":"2023","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmcl.2024.130008_b0110","doi-asserted-by":"crossref","first-page":"12442","DOI":"10.1021\/acsomega.2c01530","article-title":"Serendipitous Discovery of a Highly Active and Selective Resistance-Modifying Agent for Colistin-Resistant Gram-Negative Bacteria","volume":"7","author":"Gao","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.bmcl.2024.130008_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128878","article-title":"Structure\u2013activity relationship studies of [1,2,5]oxadiazolo[3,4-b]pyrazine-containing polymyxin-selective resistance-modifying agents","volume":"72","author":"Dutta","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2024.130008_b0120","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1021\/acs.jmedchem.9b01440","article-title":"[1,2,5]Oxadiazolo[3,4-b]pyrazine-5,6-diamine Derivatives as Mitochondrial Uncouplers for the Potential Treatment of Nonalcoholic Steatohepatitis","volume":"63","author":"Childress","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.130008_b0125","doi-asserted-by":"crossref","first-page":"6203","DOI":"10.1021\/acs.jmedchem.0c00542","article-title":"6-Amino[1,2,5]oxadiazolo[3,4-b]pyrazin-5-ol Derivatives as Efficacious Mitochondrial Uncouplers in STAM Mouse Model of Nonalcoholic Steatohepatitis","volume":"63","author":"Salamoun","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.130008_b0130","unstructured":"CDC. CDC and FDA Antimicrobial Resistance Isolate Bank. Antimicrobial Resistance. August 12, 2024. Accessed August 21, 2024. https:\/\/www.cdc.gov\/antimicrobial-resistance\/php\/public-health-strategy\/index.html."},{"key":"10.1016\/j.bmcl.2024.130008_b0140","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1128\/AAC.00497-10","article-title":"Synergy Testing by Etest, Microdilution Checkerboard, and Time-Kill Methods for Pan-Drug-Resistant Acinetobacter baumannii","volume":"54","author":"Sopirala","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2024.130008_bib141","unstructured":"CLSI M100. Perfomance Standards for Antimicrobial Susceptibility Testing. 2024. 34th ed."}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24004104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24004104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T21:02:09Z","timestamp":1733173329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X24004104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":28,"alternative-id":["S0960894X24004104"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.130008","relation":{},"ISSN":["0960-894X"],"issn-type":[{"type":"print","value":"0960-894X"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extended structure-activity relationship studies of the [1,2,5]oxadiazolo[3,4-b]pyrazine-containing colistin adjuvants","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.130008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130008"}}